The autologous, apoptotic, leukemic cells (Apo-DC) vaccine was given to 2 cohorts of patients: without additional adjuvants and with GM-CSF as an adjuvant. These two cohorts were monitored for 52 weeks. The clinical and immune monitoring data is being currently analyzed.

Autologous DC were pulsed with apoptotic allogenic prostate carcinoma cell line LNCap to produce the advanced prostate carcinoma vaccine.

These carcinoma cells were used to pulse autologous DCs for vaccine production for ovarian carcinoma patients.

We are collecting ascitic fluid (and blood) of ovarian cancer patients to study the presence of immature myeloid populations as compared to healthy donor blood. We have identified two candidate populations that will be tested for the ability to suppress T cells.

We evaluated the capacity of autologous DC and HEK293 cells transfected with relevant HLA alleles to function as T cell targets in Elispot assays upon transfection with tumor antigen encoding plasmids. Due to strong background from the autologous DC we decided that HEK293 transfected with one HLA-allele at a time plus simultaneously transfected with up to 5 tumor antiges would be optimal to screen for antigen specificity in the patients T cells. However, during a second T cell culture to expand large numbers of T cells for this screening procedure a drastic ex...

These cells were used to produce a vaccine for prostate carcinoma and were pulsed with apoptotic allogenic prostate carcinoma cell line LNCap cells.

The autologous DC loaded with KLH, as immunological tracer, and an allogeneic peptidome (i.e. natural tumour peptides, NTPs), obtained from melanoma cell line SK-Mel24, are used for vaccination.

These dendritic cells were generated from adherent peripheral blood monocytes, subject to quality controls, and subsequently used for intradermal administration in HLA-A1 and HLA-A2 positive patients with stage III/IV melanoma (V administrations with eventual additional ones depending on clinical outcome).

These autologous dendritic cells were used for vaccine production. They were pulsed with apoptotic autologous ovarian carcinoma cells.

These autologous DC were electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3) to produce a vaccine for immunotherapy of advanced melanoma patients.

These autologous DC were used in a phase IB/II study of immunotherapy. Patients were randomized to receive immunizations either with I3 DC (DC generated with interferon-beta and interleukin-3) or with G4 DC (DC generated with GM-CSF and IL-4).

The T blasts are used to immunize MAGE-3 positive patients.

These T cells were generated from the Leukapheresis product, after elutration, of a metastatic lesion of stage III/IV melanoma patients, expanded by co-culture with tumor lysate loaded DC.

The autologous T lymphocytes were stimulated with (frozen) MoDC at a ratio of 1 DC per 10 T cells.

B cell proliferation (polyclonal, oligoclonal, monoclonal) was observed in human Hemato-Lymphoid System Rag2-/-gc-/- mice after being infected with EBV and mounting an immune response.

The B-CLL patients were vaccinated with autologous, apoptotic, leukemic cells (Apo-DC). The first cohort of patients received the vaccine without additional adjuvants, while the next cohort of 5 patients who receive the vaccine with GM-CSF as an adjuvant. Clinical trial on vaccination of B-CLL patients with autologous, apoptotic, leukemic cells (Apo-DC), progressed further in 2007. Cohort 1 with the vaccine alone and cohort 2 (5 patients) combining the vaccine together with GM-CSF as an adjuvant has finished accrual and all patients in these two cohorts have ...

The B16TRex cell line cells were transfected with Bims to induce apoptosis.

B16TRex cell line cells were transfected with Fadd-dd to induce necrosis.

This colony of transgenic mice that over-express the rat HER-2/neu oncogene under the MMTV promoter were used to study new strategies of DC-based and other therapies for advanced breast cancer. Founders were provided by Forni, Torino IT.

To address the issue whether infected DC process pathogen-derived antigen and stimulate antigen-specific CD4+ T cells in vivo, we have infected susceptible BALB/c (H2-d) mice with a recombinant Leishmania major parasite expressing a fluorescent tracer. We have directly visualized antigen-presenting cells using a mAb reacting to an antigenic peptide derived from the parasite LACK antigen bound to I-Ad MHC class II molecule. I-Ad/LACK complexes were readily detected at the surface of freshly purified parasite-containing DC which expressed a CD8?- CD11b+ F4/80+ g...